ACL Relative Valuation - Australian Clinical Labs Ltd

Watchlist Manager

Watchlist

Price: 2.07 AUD 0.49% Market Closed

Market Cap: AU$397.9m

	Australian Clinical Labs Ltd ASX:ACL	AU
	Rhythm Biosciences Ltd ASX:RHY	AU
	Integral Diagnostics Ltd ASX:IDX	AU

Multiples-Based Value

The Multiples-Based Value of one ACL stock under the Base Case scenario is 4.84 AUD. Compared to the current market price of 2.07 AUD, Australian Clinical Labs Ltd is Undervalued by 57%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is relative valuation?

How is Multiples-Based Value calculated?

ACL Multiples-Based Value

Base Case

Undervaluation 57%

Multiples-Based Value

Price AU$2.07

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
AU		Australian Clinical Labs Ltd ASX:ACL	395.8m AUD	0.5	15	9.5	9.5
US		CVS Health Corp NYSE:CVS	100.8B USD	0.3	57	14.4	14.4
US	C	Cigna Group XMUN:CGN	69.6B EUR	0.3	13.4	7.8	10
US		Cigna Corp NYSE:CI	71.5B USD	0.3	12	0	0
DE		Fresenius SE & Co KGaA XETRA:FRE	25.2B EUR	1.1	19.9	9.9	14.7
DE		Fresenius Medical Care AG XMUN:FME	23.7B EUR	1.2	24.2	9.3	17.1
US		Laboratory Corporation of America Holdings NYSE:LH	21.4B USD	1.5	24.5	11.8	17.1
US		Quest Diagnostics Inc NYSE:DGX	21.1B USD	1.9	21.3	11.6	15.6
DE	F	Fresenius Medical Care AG & Co KGaA XETRA:FME	11.3B EUR	0.6	11.5	5.5	10.1
US		Guardant Health Inc NASDAQ:GH	10.3B USD	10.5	-24.7	-27.1	-24.6
US		DaVita Inc NYSE:DVA	10.3B USD	0.8	13.8	7.1	9.7

				Revenue Growth	P/S to Growth
AU		Australian Clinical Labs Ltd ASX:ACL	Average P/S: 1.7 0.5	3%	0.2
US		CVS Health Corp NYSE:CVS	0.3	4%	0.1
US	C	Cigna Group XMUN:CGN	0.3	6%	0
US		Cigna Corp NYSE:CI	0.3	6%	0
DE		Fresenius SE & Co KGaA XETRA:FRE	1.1	5%	0.2
DE		Fresenius Medical Care AG XMUN:FME	1.2	2%	0.6
US		Laboratory Corporation of America Holdings NYSE:LH	1.5	6%	0.3
US		Quest Diagnostics Inc NYSE:DGX	1.9	5%	0.4
DE	F	Fresenius Medical Care AG & Co KGaA XETRA:FME	0.6	2%	0.3
US		Guardant Health Inc NASDAQ:GH	10.5	29%	0.4
US		DaVita Inc NYSE:DVA	0.8	4%	0.2

				Earnings Growth	PEG
AU		Australian Clinical Labs Ltd ASX:ACL	Average P/E: 21.3 15	6%	2.5
US		CVS Health Corp NYSE:CVS	57	90%	0.6
US	C	Cigna Group XMUN:CGN	13.4	19%	0.7
US		Cigna Corp NYSE:CI	12	19%	0.6
DE		Fresenius SE & Co KGaA XETRA:FRE	19.9	25%	0.8
DE		Fresenius Medical Care AG XMUN:FME	24.2	15%	1.6
US		Laboratory Corporation of America Holdings NYSE:LH	24.5	27%	0.9
US		Quest Diagnostics Inc NYSE:DGX	21.3	12%	1.8
DE	F	Fresenius Medical Care AG & Co KGaA XETRA:FME	11.5	15%	0.8
US		Guardant Health Inc NASDAQ:GH	Negative Multiple: -24.7	N/A	N/A
US		DaVita Inc NYSE:DVA	13.8	19%	0.7

				EBITDA Growth	EV/EBITDA to Growth
AU		Australian Clinical Labs Ltd ASX:ACL	Average EV/EBITDA: 9.7 9.5	48%	0.2
US		CVS Health Corp NYSE:CVS	14.4	28%	0.5
US	C	Cigna Group XMUN:CGN	7.8	5%	1.6
US		Cigna Corp NYSE:CI	Not Available	N/A	N/A
DE		Fresenius SE & Co KGaA XETRA:FRE	9.9	10%	1
DE		Fresenius Medical Care AG XMUN:FME	9.3	7%	1.3
US		Laboratory Corporation of America Holdings NYSE:LH	11.8	10%	1.2
US		Quest Diagnostics Inc NYSE:DGX	11.6	6%	1.9
DE	F	Fresenius Medical Care AG & Co KGaA XETRA:FME	5.5	7%	0.8
US		Guardant Health Inc NASDAQ:GH	Negative Multiple: -27.1	N/A	N/A
US		DaVita Inc NYSE:DVA	7.1	4%	1.8

				EBIT Growth	EV/EBIT to Growth
AU		Australian Clinical Labs Ltd ASX:ACL	Average EV/EBIT: 13.1 9.5	3%	3.2
US		CVS Health Corp NYSE:CVS	14.4	22%	0.7
US	C	Cigna Group XMUN:CGN	10	5%	2
US		Cigna Corp NYSE:CI	Not Available	N/A	N/A
DE		Fresenius SE & Co KGaA XETRA:FRE	14.7	12%	1.2
DE		Fresenius Medical Care AG XMUN:FME	17.1	11%	1.6
US		Laboratory Corporation of America Holdings NYSE:LH	17.1	18%	0.9
US		Quest Diagnostics Inc NYSE:DGX	15.6	9%	1.7
DE	F	Fresenius Medical Care AG & Co KGaA XETRA:FME	10.1	11%	0.9
US		Guardant Health Inc NASDAQ:GH	Negative Multiple: -24.6	N/A	N/A
US		DaVita Inc NYSE:DVA	9.7	5%	1.9

Australian Clinical Labs Ltd
ASX:ACL

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

ACL Competitors Multiples
Australian Clinical Labs Ltd Competitors

See Also

Company

Help

Tools

Stocks

Australian Clinical Labs Ltd ASX:ACL

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

ACL Competitors Multiples Australian Clinical Labs Ltd Competitors

See Also

Company

Help

Tools

Stocks

Australian Clinical Labs Ltd
ASX:ACL

ACL Competitors Multiples
Australian Clinical Labs Ltd Competitors